Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GINAKIT CAR-NKT Cells for Neuroblastoma
NCT02439788Phase 1Withdrawn
- Sponsor
- Baylor College of Medicine
- Start
- Aug 2017
- Primary completion
- Sep 2019
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GINAKIT Cells in neuroblastoma, sponsored by Baylor College of Medicine. Primary endpoint: Dose Limiting Toxicities at 4 weeks. Planned start Aug 2017; status: withdrawn.
02
Drugs
GINAKIT Cells
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02439788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02439788.